Top Page
Arecor Therapeutics PLC
(LSE:AREC)
Arecor Therapeutics PLC (AREC) vs. iShares MSCI United Kingdom ETF (EWC)
Arecor Therapeutics PLC Business Overview & Revenue Model
Arecor Therapeutics PLC Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 5.05M | 4.57M | 2.40M | 1.16M | 1.70M | Gross Profit |
| 1.54M | 4.57M | 2.06M | 1.16M | 1.70M | EBIT |
| -10.70M | -9.18M | -10.63M | -5.98M | -3.43M | EBITDA |
| -10.15M | -8.39M | -10.06M | -6.27M | -3.26M | Net Income Common Stockholders |
| -10.24M | -8.55M | -9.26M | -6.17M | -2.75M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.26M | 6.75M | 12.81M | 18.32M | 2.90M | Total Assets |
| 8.72M | 15.38M | 21.77M | 20.92M | 4.28M | Total Debt |
| 232.00K | 338.00K | 288.00K | 231.00K | 2.00M | Net Debt |
| -3.01M | -4.75M | -4.48M | -18.09M | -903.11K | Total Liabilities |
| 3.37M | 5.85M | 4.31M | 2.37M | 3.51M | Stockholders Equity |
| 5.35M | 9.53M | 17.45M | 18.55M | 773.79K |
| Cash Flow | Free Cash Flow | |||
| -9.18M | -5.99M | -11.13M | -5.52M | -1.91M | Operating Cash Flow |
| -9.15M | -5.84M | -10.78M | -5.45M | -1.86M | Investing Cash Flow |
| 1.72M | 6.52M | -7.99M | -68.00K | -49.32K | Financing Cash Flow |
| 5.65M | -180.00K | 5.16M | 20.93M | 1.77M |
Arecor Therapeutics PLC Technical Analysis
Arecor Therapeutics PLC Peers Comparison
Arecor Therapeutics PLC Corporate Events
Arecor Therapeutics plc announced the grant of 295,000 options under its Long Term Incentive Plan and 239,600 options under its All Employee Share Ownership Plan. These options are part of the company’s strategy to incentivize its leadership and employees, with performance conditions tied to time and share price outperformance. This move is likely to strengthen employee commitment and align their interests with the company’s long-term growth objectives.
Arecor Therapeutics plc announced the successful passage of all resolutions at its Annual General Meeting, with one resolution deemed redundant and bypassed. This outcome reinforces the company’s governance and operational strategies, potentially strengthening its position in the biopharmaceutical industry and providing reassurance to stakeholders.
Arecor Therapeutics plc announced the retirement of Dr. Alan E Smith from his role as a Non-Executive Director after over 17 years of service. Dr. Smith’s scientific and strategic guidance has been pivotal in advancing Arecor from its early stages to a clinical-stage company. His departure marks a significant change in the board, but the company remains confident in its future success as it continues to develop its promising pipeline of therapeutics.
Arecor Therapeutics plc announced that key executives, including Chair Andrew Richards, CEO Sarah Howell, and CSO Jan Jezek, have purchased ordinary shares in the company. This move signifies confidence in the company’s future prospects and may positively influence stakeholder perceptions, potentially strengthening Arecor’s position in the biopharmaceutical industry.
Arecor Therapeutics has partnered with Skye Bioscience to develop an enhanced formulation of nimacimab, a CB1 inhibitor for obesity treatment, using Arecor’s Arestat™ technology. This collaboration underscores Arecor’s strategic focus on innovative medicine development and offers significant potential for future licensing opportunities, while addressing unmet needs in metabolic disease treatment.
Arecor Therapeutics plc announced that Andrew Richards, the Chair of the company, has purchased 35,000 ordinary shares at £0.4125 each, increasing his total beneficial interest to 286,611 shares, which represents 0.76% of the total voting rights. This transaction reflects a significant vote of confidence in the company’s future prospects and may positively influence stakeholder perceptions and market positioning.
Arecor Therapeutics plc has released its Annual Report and Accounts for the year ending December 31, 2024, and announced its Annual General Meeting scheduled for June 2, 2025. This announcement provides shareholders with updated financial information and strategic insights, potentially impacting investor confidence and the company’s market positioning.
Arecor Therapeutics plc announced that its CEO, Sarah Howell, and CFO, David Ellam, will present the company’s final results for the year ended 31 December 2024 on the Investor Meet Company platform on 1 May 2025. This presentation is accessible to both existing and potential shareholders, allowing them to submit questions in advance or during the live session. This initiative reflects Arecor’s commitment to transparency and engagement with its stakeholders, potentially enhancing its market presence and investor relations.
Arecor Therapeutics plc announced the grant of 230,000 options to its Chief Financial Officer, David Ellam, under the company’s Long Term Incentive Plan and All Employee Share Ownership Plan. This move is part of Arecor’s strategy to incentivize and retain key management personnel, potentially impacting the company’s operational focus and aligning management interests with shareholder value.
Arecor Therapeutics reported its final results for 2024, highlighting significant progress in its diabetes portfolio and the potential for innovation in oral peptide delivery. The company achieved a total revenue of £5.1 million, with advancements in its ultra-concentrated insulin candidate, AT278, and a new collaboration for oral peptide delivery. Despite a loss after tax of £10.2 million, Arecor remains focused on high-value R&D opportunities and expanding its partnership portfolio, positioning itself for future growth and success.
Arecor Therapeutics plc announced it will release its audited final results for the year ended 31 December 2024 on 22 April 2025. The announcement will include an in-person briefing for analysts, along with a live webcast and conference call, indicating the company’s commitment to transparency and engagement with stakeholders.
Arecor Therapeutics has entered into a collaboration with a major global pharmaceutical company to develop a novel formulation of the partner’s proprietary product using Arecor’s Arestat™ technology. This partnership, which is fully funded by the partner, underscores Arecor’s leadership in drug delivery and formulation innovation, potentially leading to future licensing opportunities and enhancing its market positioning.